Panaich Sidakpal S, Eleid Mackram F
Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
Ann Transl Med. 2016 Oct;4(20):410. doi: 10.21037/atm.2016.10.44.
Redo surgery for bioprosthetic tricuspid valve failure is associated with high morbidity and mortality. In recent years, transcatheter tricuspid valve-in-valve (VIV) therapy utilizing ballon-expandable transcatheter valves has become available. The tricuspid Valve-in-Valve International Data (VIVID) registry initial results represent the largest experience with tricuspid VIV therapy, demonstrating high procedural success rates with low 30 days mortality and excellent survival free of repeat tricuspid intervention in 1 year. Although longer clinic and hemodynamic follow-up will be needed to fully understand the role of this therapy, these data support the safety, feasibility and beneficial effects of tricuspid VIV therapy. For patients with bioprosthetic tricuspid valve failure, tricuspid VIV is likely to become a first-line treatment option.
生物瓣三尖瓣功能障碍再次手术与高发病率和死亡率相关。近年来,利用球囊扩张经导管瓣膜的经导管三尖瓣瓣中瓣(VIV)治疗已应用于临床。三尖瓣瓣中瓣国际数据库(VIVID)登记的初步结果代表了三尖瓣VIV治疗的最大经验,显示出高手术成功率、低30天死亡率以及1年内无需再次进行三尖瓣干预的良好生存率。尽管需要更长时间的临床和血流动力学随访来全面了解该治疗方法的作用,但这些数据支持三尖瓣VIV治疗的安全性、可行性和有益效果。对于生物瓣三尖瓣功能障碍患者,三尖瓣VIV可能会成为一线治疗选择。